Abstract: Provided are: a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion-transporting receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin and a nucleic acid sequence encoding a signal sequence; and a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion channeling receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin; and a nucleic acid construct including the nucleic acid sequences. The use of the nucleic acids or nucleic acid constructs prevents and suppresses the progress of retinal diseases, and enhances the visual cognitive behavioral function and visual function.

Abstract: Provided are: a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion-transporting receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin and a nucleic acid sequence encoding a signal sequence; and a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion channeling receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin; and a nucleic acid construct including the nucleic acid sequences. The use of the nucleic acids or nucleic acid constructs prevents and suppresses the progress of retinal diseases, and enhances the visual cognitive behavioral function and visual function.

Abstract: The present invention provides a method for evaluating tumorigenicity of a test cell, including transplanting the cell into anterior chamber of an eye of an experimental animal, and observing the presence or absence of tumor formation. According to the present invention, tumorigenicity can be evaluated in a short period and conveniently.

Abstract: Provided are a chimeric protein of two types of rhodopsins, an ion-transporting rhodopsin and a G protein-coupled receptor rhodopsin, and a nucleic acid encoding the same, for the prevention and suppression of progression of retinal diseases, the improvement in visual cognitive behavioral functions (e.g., improvement in light-dark determination functions, improvement in bright spot evading functions, and/or crisis avoidance functions), and the enhancement of visual functions (e.g., improvement in visual acuity). The present invention also provides a method for preventing or suppressing the progression of a disease, disorder or symptom of the retina, for improving a visual cognitive behavioral function (e.g., improvement in light-dark determination functions, improvement in bright spot evading functions, and/or crisis avoidance functions), or for enhancing visual functions (e.g.

Abstract: To provide a brain wave and cell activity control device and method based on light stimulation in which light having a specific wavelength, such as violet light, is irradiated using continuous light or a specific blinking frequency, and a device for improvement, prevention, or increase in brain function. The above-described problem is solved by a brain wave and cell activity control device, based on light stimulation, that controls brain waves or cell activity by irradiating light having a specific wavelength onto a subject using continuous light or a specific blinking frequency.

Abstract: A light source for myopia prevention article includes a light emitter to emit light having an emission spectrum continuing from a first wavelength of not less than 360 nm nor more than 400 nm to a second wavelength of more than 400 nm.

Abstract: This invention provides a prophylactic and therapeutic agent for dry eye, having new ingredients to reduce the deterioration of the lacrimal secretory ability and to inhibit the generation of radical oxygen in lacrimal gland tissue. The prophylactic and therapeutic agent for dry eye of this invention contains the maqui berry extract as the active substance of this invention, i.e. containing delphinidin glycoside extracted from the maqui berry and at least one or more of the active substances delphinidin-3-sambubioside-5-glucoside, delphinidin-3,5-diglucoside, delphinidin-3-sambubioside and delphinidin-3-glucoside, preferably delphinidin-3,5-diglucoside.

Abstract: A light source for myopia prevention article includes a light emitter to emit light having an emission spectrum continuing from a first wavelength of not less than 360 nm nor more than 400 nm to a second wavelength of more than 400 nm.

Abstract: To provide a device and a method for strengthening a cornea or a sclera or suppressing a progression of a disease in a non-invasive manner, enabling treatment in daily life without treatment in a confined state at a medical institution for a fixed period of time and without ablation of the corneal epithelium as in conventional corneal crosslinking. The above-described problem is solved by a non-invasive cornea and sclera strengthening device that irradiates violet light toward an eye administered with an administration agent used to strengthen a corneal tissue or a scleral tissue, and is configured so that an irradiance of the violet light onto a surface of the eye is within a range of 0.1 to 1 mW/cm2, and a time of irradiation of the violet light onto the eye is within a range of one to five hours per day.

Abstract: A device for supporting diagnosis has: a reception unit that is configured to receive a fundus image of a subject eye; an identification unit provided with a trained model that is configured to recognize, in the fundus image of the subject eye, an area of abnormality in blood circulation, wherein the model has been trained based upon an image of a fundus and an area of abnormality in blood circulation specified in a fluorescent angiography image of the fundus; and an output unit that is configured to output information relating to the area of abnormality in blood circulation recognized in the fundus image of the subject eye.

Abstract: Using the medium of the present invention for inducing a cornea endothelial substitute cell from an iPS cell, the medium containing an insulin-like growth factor and a STAT3 activator, and not containing a basic fibroblast growth factor or a ROCK inhibitor, and the method of the present invention for inducing corneal endothelial substitute cells from iPS cells by using the medium, it becomes possible to efficiently produce corneal endothelial substitute cells, particularly to efficiently produce corneal endothelial substitute cells from iPS cells. Furthermore, it becomes possible to stably produce large amounts of corneal endothelial substitute cells by inducing differentiation of iPS cells into corneal endothelial substitute cells more efficiently.

Abstract: An optical element has a transmission spectrum characterized in that a local maximum falls within a wavelength region longer than 315 nm but shorter than or equal to 400 nm, a local minimum falls within a wavelength region longer than or equal to 380 nm but shorter than or equal to 500 nm, and the wavelength at the local maximum is shorter than the wavelength at the local minimum.

Abstract: A wavelength-selective transmissive glass has a light transmittance Tmore than 315 nm and 400 nm or less at a wavelength of more than 315 nm and 400 nm or less represented by the formula shown below of 1% or more in terms of a plate thickness of 6 mm and a light transmittance T315 nm or less at a wavelength of 315 nm or less represented by the formula shown below of 60% or less in terms of a plate thickness of 6 mm. Ak is a weighting factor at a wavelength k (nm) for calculating T (light transmittance) defined in ISO-9050:2003, and Tk is a transmittance at the wavelength k (nm) in terms of a plate thickness of 6 mm: Tmore than 315 nm and 400 nm or less=(?k=more than 315400Ak×Tk)/(?k=more than 315400Ak) T315 nm or less=(?k=300315Ak×Tk)/(?k=300315Ak).

Abstract: The purpose of the present invention is to provide a myopia treatment device. A myopia treatment device of the present invention comprises a light transmission part selected from a group consisting of an eyesight correcting tool, an eye protection tool, a face protection tool, a sunshade, a display device, a window, a wall, a light source covering, and a coating material. The light transmission part of the device transmits violet light having a wavelength within a range of 360 nm to 400 nm inclusive and thus treats myopia. Or, the myopia treatment device comprises a light emission part selected from a group consisting of lighting equipment, a display device, and a light irradiation device. The light emission part of the device emits violet light having a wavelength within a range of 360 nm to 400 nm inclusive and thus treats myopia.

Abstract: The present invention provides a method for evaluating tumorigenicity of a test cell, including transplanting the cell into anterior chamber of an eye of an experimental animal, and observing the presence or absence of tumor formation. According to the present invention, tumorigenicity can be evaluated in a short period and conveniently.

Abstract: To provide a spraying device and a spraying method for moisture mist that supply at least a micro liquid to the eye, and can be used for dry eye symptom relief, drug delivery, allergy prevention, relaxation, and the like. The above-described problem is solved by a spraying device (1, 31) that supplies at least a micro liquid, and includes a spraying element (16) that sprays a mist-like substance containing the micro liquid onto a local region (50). The raw material is a liquid raw material or a solid raw material that may include a medicinal additive. The medicinal additive is preferably selected from among menthol, analgesics, antibiotics, antiallergic agents, steroids, intraocular pressure-lowering agents, and the like. The spraying device (1, 31) may be an eyeglasses-type spraying device (1) in which the local region (50) is configured by a rim (3) and a temple (6) of eyeglasses, or a cup-type spraying device (31) in which the local region (50) includes an opening (32).

Abstract: The ophthalmic composition effective for the prevention or treatment of myopia or ocular diseases are provided. In particular, the present invention provides an ophthalmic composition effective in a growing child or a young person in whom myopia develops and progresses, as well as a middle-aged and elderly person in whom age-related ocular diseases such as cataract, glaucoma, retinal detachment, retinopathy, maculopathy, choroidal neovascularization, posterior staphyloma, and optic neuropathy develop, a functional food containing the ophthalmic composition, and a screening method capable of searching for the same. [Solution] The above problem is solved by an ophthalmic composition or functional food product containing at least one component selected from the group consisting of crocetin and its pharmaceutically acceptable salts and ginkgo leaf extract.

Abstract: To provide a display system such as a smartphone, a game console, a personal computer, or a liquid crystal television, including a light-emitting element that irradiates light having a specific wavelength toward a user. The above-described problem is solved by a display system (1) including a first light-emitting element (6) that emits light used for image display, a second light-emitting element (3) that irradiates light (7) within a wavelength range of 360 nm to 400 nm, inclusive, toward a user, and a control unit (10) that controls irradiation of the light (7) from the second light-emitting element (3).At this time, the second light-emitting element (3) may be a single light-emitting element integrated with the first light-emitting element (6) or a light-emitting element provided separately from the first light-emitting element (6).

Abstract: A model that closely resembles human excessive myopia can be prepared by mounting a minus lens (2) and a protector (4) to a juvenile mouse, the minus lens having an angle and a width adjustable in response to growth of the mouse. Further, this model analysis shows that myopia induction causes endoplasmic reticulum stress in a sclera and the endoplasmic reticulum stress induces myopia. Furthermore, it is revealed that an endoplasmic reticulum stress suppressant, particularly, phenylbutyrate and tauroursodeoxycholic acid act as a myopia prevention/suppression agent.

Abstract: To provide a display system such as a smartphone, a game console, a personal computer, or a liquid crystal television, including a light-emitting element that irradiates light having a specific wavelength toward a user. The above-described problem is solved by a display system (1) including a first light-emitting element (6) that emits light used for image display, a second light-emitting element (3) that irradiates light (7) within a wavelength range of 360 nm to 400 nm, inclusive, toward a user, and a control unit (10) that controls irradiation of the light (7) from the second light-emitting element (3). At this time, the second light-emitting element (3) may be a single light-emitting element integrated with the first light-emitting element (6) or a light-emitting element provided separately from the first light-emitting element (6).